Library Header Image
LSE Research Online LSE Library Services

Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps

Simpkin, Victoria L., Renwick, Matthew J., Kelly, Ruth and Mossialos, Elias ORCID: 0000-0001-8664-9297 (2017) Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. Journal of Antibiotics, 70 (12). pp. 1087-1096. ISSN 0021-8820

Text - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.

Download (2MB) | Preview
Identification Number: 10.1038/ja.2017.124


Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Based on a literature review and expert input, this study first identifies and assesses the major international, European Union, US and UK antibiotic R&D funding programmes. These programmes are then evaluated across market and public health criteria necessary for comprehensively improving the antibiotic market. The current set of incentive programmes are an important initial step to improving the economic feasibility of antibiotic development. However, there appears to be a lack of global coordination across all initiatives, which risks duplicating efforts, leaving funding gaps in the value chain and overlooking important AMR goals. This study finds that incentive programmes are overly committed to early-stage push funding of basic science and preclinical research, while there is limited late-stage push funding of clinical development. Moreover, there are almost no pull incentives to facilitate transition of antibiotic products from early clinical phases to commercialisation, focus developer concentration on the highest priority antibiotics and attract large pharmaceutical companies to invest in the market. Finally, it seems that antibiotic sustainability and patient access requirements are poorly integrated into the array of incentive mechanisms

Item Type: Article
Official URL:
Additional Information: © 2017 The Authors © CC BY-NC-SA 4.0
Divisions: LSE Health
Subjects: H Social Sciences > HJ Public Finance
R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited: 12 Jan 2018 16:30
Last Modified: 04 Jul 2024 05:45
Projects: 1-RHE-C390
Funders: Ministry of Health, Welfare and Sport, The Netherlands

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics